Year All2024202320222021202020192018201720162015 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel July 16, 2020 Poseida Therapeutics Announces Pricing of Initial Public Offering July 9, 2020 Poseida Therapeutics Raises $110 Million in Series D Financing June 25, 2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019 Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer October 10, 2019 Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma May 13, 2019 Poseida Therapeutics Raises $142 Million in Series C Financing April 22, 2019 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks February 13, 2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions January 4, 2019
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019
Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma May 13, 2019
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks February 13, 2019
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions January 4, 2019
